Menopausal Syndrome Clinical Trial
— IMGTMPOfficial title:
Internet- and Mobile-based Group Treatment of Menopausal and Psychological Health of Chinese Women: a Study Protocol for a Randomized Non-inferiority Trial
Verified date | May 2019 |
Source | Southeast University, China |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Background: Menopause syndrome generally occurs with and is related to psychological
problems. However, Internet- and mobile-based group treatment (imGT) may improve women's
physiological and psychological conditions.
Objective: To investigate the efficacy of group treatment with or without Internet- and
mobile-based treatment of menopause, mood swings and quality of life status.
Methods: This protocol is for a randomized controlled clinical trial with a sample of 144
menopausal women divided into 2 groups: imGT and face-to-face group treatment (ffGT). The
primary outcome will be the menopausal symptom improvement of the two groups, as assessed by
Greene Climacteric Scale. The secondary outcomes will be quality of life, assessed by the
Short Form 36 Health Survey Questionnaire; insomnia, assessed by the Pittsburgh Sleep Quality
Inventory; anxiety, assessed by the Hamilton Anxiety Rating Scale; and therapeutic alliance,
assessed by the Working Alliance Inventory-Short Revised. imGT will be performed once a week
for 1.5 hours for 10 weeks with a daily Punched-in on the WeChat App; ffGT will be performed
once a week for 1.5 hours for 10 weeks. All outcomes will be assessed at baseline, at a
post-intervention evaluation (week 10), and at a follow-up evaluation (week 22).
Discussion: This study will be the first clinical trial to examine the effects of imGT on
menopausal women in China. If imGT is found to be equivalent to or superior to ffGT, it will
facilitate easier access to menopausal health services, which may be feasible to offer to
other medical institution.
Status | Enrolling by invitation |
Enrollment | 140 |
Est. completion date | August 31, 2020 |
Est. primary completion date | March 31, 2020 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 40 Years to 60 Years |
Eligibility |
Inclusion Criteria: - aged 40~60, in menopausal transition or post-menopause, according to the STRAW +10 definition - have Internet access - have mobile phone access - have sufficient knowledge of the Chinese language - have scored in the clinical range for menopause syndrome from the psychiatric interview - have signed a consent form that will be provided to eligible participants. Exclusion Criteria: - not completing informed consent - presence of any of the following diseases: hyperthyroidism, coronary atherosclerotic heart disease, hypertension (BP=140/90 mmHg), pheochromocytoma, neurasthenia, psychosis, or other diseases closely related to the main disease - troublesome drinking - drug use (hypnotics or hormone therapy) in the past 14 days, which might affect mood. |
Country | Name | City | State |
---|---|---|---|
China | the Affiliated Obstetrics and Gynaecology Hospital of Nanjing Medical University | Nanjing | Jiangsu |
Lead Sponsor | Collaborator |
---|---|
Southeast University, China | The Affiliated Obstetrics and Gynecology Hospital of Nanjing Medical University |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Greene Climacteric Scale | Greene Climacteric Scale is used for evaluating menopausal symptoms. It contains 21 questions covering 5 domains: anxiety, depression, somatic symptoms, vasomotor symptoms, and sexual function. Each question is answered on a 4-point Likert scale. The answers to all 21 questions are summed to give a total quality-of-life measure; a higher score indicates a worse quality of life. According to the hypothesis and PRO-specific domains of this trial, vasomotor symptoms, anxiety and depression will be analysed specifically. The Chinese version of this questionnaire has a high validation (0.90), and the Cronbach's alpha coefficient is 0.95, while its test-retest reliability is 0.94 (P <0.01). | week 0 | |
Primary | Greene Climacteric Scale | Menopause symptoms after 10 sessions of group cognitive behavioral therapy | week 10 | |
Primary | Greene Climacteric Scale | Menopause symptoms of one follow-up meeting | week 22 | |
Secondary | The Short Form 36 Health Survey Questionnaire | The Short Form 36 Health Survey Questionnaire (SF36) is widely used for evaluating the potential benefits of healthcare interventions. It is comprised of eight dimensions (including physical functioning, social functioning, role limitations, mental health, energy/vitality, pain, general health perceptions), and the score ranges from 0 to 100, where better health achieves higher scores. This questionnaire was chosen because of the validation of the Chinese version with a sensitivity of 0.72~0.88 and specificity of 87.5%~100%. | week 0 | |
Secondary | The Short Form 36 Health Survey Questionnaire | Quality of life | week 10 | |
Secondary | The Short Form 36 Health Survey Questionnaire | Quality of life | week 22 | |
Secondary | Pittsburgh Sleep Quality Index | The Pittsburgh Sleep Quality Index (PSQI) is a self-rating inventory that evaluates sleep quality and disturbances within a 4-week time interval. It comprises 19 individual items with a global score ranging from 0 to 21. The correlation coefficient of PSQI for t-test reliability was 0.87. A Chinese PSQI score >7 yielded a sensitivity of 98.3% and specificity of 90.2% in distinguishing between good and poor sleepers (kappa= 0.89, p<0.01) | week 0 | |
Secondary | Pittsburgh Sleep Quality Index | Insomnia | week 10 | |
Secondary | Pittsburgh Sleep Quality Index | Insomnia | week 22 | |
Secondary | The Hamilton Anxiety Rating Scale | The Hamilton Anxiety Rating Scale (HAM-A) is a rating scale developed to measure the symptoms of anxiety neurosis. It is a semi-structured clinician-rated interview consisting of 14 items that measure both psychological anxiety and somatic anxiety. A 5-point scale ranging from 0 (not present) to 4 (severe) is used, where the total severity score is 0-56; <17 indicates mild anxiety and 25-30 is considered moderate-severe. The Chinese version of HAM-A will be used in this study. | week 0, 10, 22 | |
Secondary | The Hamilton Anxiety Rating Scale | Anxiety | week 10 | |
Secondary | The Hamilton Anxiety Rating Scale | Anxiety | week 22 | |
Secondary | The Working Alliance Inventory-Short Revised | The Working Alliance Inventory-Short Revised (WAI-SR) provides an assessment of the therapeutic alliance and contains 12 items with three dimensions of working alliance: agreement on the tasks of therapy, agreement on the goals of therapy and development of an affective bond between client and therapist. Items are rated on a 5-point scale (range from 1= "never" to 5= "always"). | week 0, 10 | |
Secondary | The Working Alliance Inventory-Short Revised | Therapeutic alliance | week 10 | |
Secondary | Client Satisfaction Qestionnaire-8 (CSQ-8) | Treatment satisfaction will be measured by the Client Satisfaction Qestionnaire-8 (CSQ-8), which evaluates the service utilization and psychotherapy outcome measures with high internal consistency (coefficient a = .91). | week 10 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01741974 -
Study of Anti-atherosclerotic and Estrogen-like Activity of Karinat in Perimenopausal Women
|
Phase 3 | |
Not yet recruiting |
NCT05522621 -
A Muticenter Clinical Study of Chinese Herbal Compound TJAOA102 in Alleviating Menopausal Syndrome
|
Early Phase 1 | |
Completed |
NCT01046643 -
Early Menopause Hormone Treatment and Cognition
|
N/A | |
Active, not recruiting |
NCT00694733 -
Regulation of Cortisol Metabolism and Fat Patterning
|
N/A | |
Completed |
NCT05759936 -
4-week Seaweed Supplementation on Menopause Symptoms and Psychological Wellbeing
|
N/A | |
Completed |
NCT05266079 -
Comparison Study for Perimenopausal Syndrome With Chinese Herbal Medicine
|
N/A | |
Completed |
NCT04520542 -
The Effect of Acupressure Application on Menopausal Symptoms
|
N/A | |
Completed |
NCT02749747 -
Sulpiride Versus Placebo for Reducting Hot Flushes During Climacteric
|
Phase 3 | |
Completed |
NCT01849172 -
Effect and Safety of Electroacupuncture for Symptoms of Menopausal Transition
|
N/A | |
Recruiting |
NCT04031456 -
Autologous PRP Infusion May Restore Ovarian Function and May Promote Folliculogenesis in POI Patients
|
Phase 2/Phase 3 | |
Recruiting |
NCT02294500 -
Cohort Study to Evaluate Ovarian Function
|
N/A | |
Completed |
NCT02467673 -
Nanoparticulate Versus Micronized Steroids Delivery for Transdermal Hormone Replacement Therapy
|
Phase 2 | |
Recruiting |
NCT05280028 -
HRT on Overactive Bladder Symptoms, Sexual Function, Depressive Symptoms, Autonomic Function, and Arterial Stiffness
|
||
Completed |
NCT00289926 -
Efficacy and Safety of Oral DHEA Therapy for Postmenopausal Women on Sexual Function, Wellbeing and Vasomotor Symptoms
|
Phase 3 | |
Recruiting |
NCT01698164 -
Multi-centre Clinical Trial on Hormone Replacement Treatment in China
|
Phase 4 | |
Completed |
NCT05463081 -
Clinical Trial of "Magic Gyno" Laser Device
|
N/A | |
Completed |
NCT00933725 -
Efficacy and Safety of Traditional Chinese Medicine Intervention for Women With Menopausal Syndrome
|
Phase 3 | |
Enrolling by invitation |
NCT02001402 -
Chinese Health Investigation of Nurse Aging
|
N/A | |
Recruiting |
NCT04726254 -
The JULI Registry--Hemp and Cannabis Observational Registry
|
||
Completed |
NCT01931748 -
A Randomized, Double-Blind, Parallel, Non-Inferiority, Multicenter Trial Evaluate the Efficacy and Safety of UNCNT Compared to MELSMON in Female With Menopausal Syndrome
|
Phase 3 |